Literature DB >> 6991029

Presence of NCA (nonspecific cross-reacting antigen) in the cells of the human granulocyte series.

P Burtin, G Flandrin, M C Fondaneche.   

Abstract

The presence of NCA (nonspecific cross-reacting antigen) in the cells of the human granulocyte series was investigated by using the immunoperoxidase technique. NCA was detected in normal bone marrow at the promyelocyte stage. It was found in leukemic myeloblasts only when they had some degree of differentiation (M2 type), but the results for promyelocytic leukemias (M3 type) were always negative. Auer rods were never stained by anti-NCA serum. In chronic myeloid leukemias, many pathologic myelocytes were positive, their intensity varying from one case to another; a relation was noted between the intensity of this reaction and the number of neutrophil granules stained by Giemsa reagent on parallel slides of the same cases. Normal-looking polymorphs were often weakly labeled or not labeled by anti-NCA serum in the bone marrow or blood of leukemic patients. Here again, a parallel was seen with the staining of neutrophil granules by Giemsa. From these data, an association between NCA and azurophilic granules can be deduced.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6991029

Source DB:  PubMed          Journal:  Blood Cells        ISSN: 0340-4684


  3 in total

1.  Relationship between myelomonocytic, myeloid and nonspecific cross-reacting (NCA) antigens during myelocytic cell differentiation.

Authors:  A Harłozińska; A Noworolska; O Majdic; R Richter; S Kotlarek-Haus
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

2.  Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series.

Authors:  A Noworolska; A Harłozińska; R Richter; W Brodzka
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

3.  An investigation of factors influencing serum NCA (non-specific cross-reacting antigen) level in patients with chronic myeloid leukaemia.

Authors:  N Frénoy; M Ben-Bunant; C Berruel; J A Child; M C Gendron; J L Missett; E Razafimahaleo; P Burtin
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.